AVBP.O (AVBP.O) News
Follow AVBP.O (AVBP.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ArriVent's firmonertinib misses Phase 3 trial goal in lung cancer
ArriVent's Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed its primary progression-free survival endpoint, with independent review showing no meaningful improvement versus chemoth
EQUITY | Oct 06, 2026, 12:40 PM UTC
M
Nasdaq resumes trading at 8:33 AM ET
EQUITY | Oct 06, 2026, 12:36 PM UTC
M
AVBP.O halted: news pending
EQUITY | Oct 06, 2026, 11:56 AM UTC